Intercept Pharmaceuticals, a firm whose treatment for a prevalent liver disease once made it the hottest stock in biotech, said Tuesday it would sell the company for less than $1 billion ...

The FDA rejected Intercept’s investigational treatment for NASH on Thursday, derailing what would have been the first approved medicine for a prevalent liver disease.

The Intercept, a nonprofit investigative news outlet, is laying off 15 staffers including Editor-in-Chief Roger Hodge. Layoffs were announced in an internal memo sent to staffers on Thursday ...

Shares of Intercept, which fell nearly 15% last week after the FDA's staff reviewers flagged serious concerns related to the drug ahead of the meeting, were down about 16% at $11.50 in early trading.

So what. Intercept is now trading at roughly $18.70 per share, which suggests that investors believe there's a very good chance that the buyout will be completed.

Feb 20 - Artificial intelligence giant OpenAI lost a bid on Thursday to dismiss a lawsuit in New York federal court alleging it misused news articles published by The Intercept to train its ...